Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Autolus Therapeutics (AUTL – Research Report) and Masimo (MASI – Research Report).
Autolus Therapeutics (AUTL)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Autolus Therapeutics, with a price target of $8.00. The company’s shares closed last Wednesday at $6.79, close to its 52-week high of $7.10.
According to TipRanks.com, Zhu is a 4-star analyst with an average return of
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $8.80.
See Insiders’ Hot Stocks on TipRanks >>
Masimo (MASI)
In a report released yesterday, Vik Chopra from Wells Fargo maintained a Hold rating on Masimo, with a price target of $81.00. The company’s shares closed last Wednesday at $120.96.
According to TipRanks.com, Chopra is a 2-star analyst with an average return of
Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $101.60, a -11.6% downside from current levels. In a report issued on January 3, Needham also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AUTL:
- Autolus Therapeutics Announces Changes to its Board of Directors
- Autolus Therapeutics appoints Leiderman to board, Dhingra to step down
- Autolus Therapeutics presents clinical data updates at ASH Annual Meeting 2023
- Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
- Autolus Therapeutics submits BLA to U.S. FDA for obecabtagene autoleucel
